Fda Decision On Experimental Alzheimer's Drug Expected This Week

CNN.com - RSS Channel - Health, CNN: Health
Mon, 01/02/2023 - 9:03am

The US Food and Drug Administration could decide this week whether to grant accelerated approval to the experimental dementia drug lecanemab, according to Eisai and Biogen, the companies that make the drug.

NEXT
Topics:  health   
RELATED ARTICLES
  • no title provided in feed
    CNN's Dr. Sanjay Gupta speaks to registered nurse Kate Carleton about her efforts to prepare schoolchildren to treat injuries suffered in a mass shooting. More
  • no title provided in feed
    These senior citizens have waited on the phone for hours, driven miles, set-up work stations so they could get a Covid-19 vaccine appointment. See who was able to get one. More
  • no title provided in feed
    The global fertility rate has fallen from 5 births per woman in 1950 to 2.3 in 2021 - and even lower in the U.S., partly due to the cost of child-rearing and shifts in priorities. But "falling population and an elderly or aging population puts a lot of fiscal and economic pressures on society," says Economics Professor Melissa Kearney. More
  • no title provided in feed
    Independent presidential candidate Robert F. Kennedy Jr. told The New York Times he experienced a series of health issues in recent years, including an abnormality that he said was caused by a worm that entered his brain and then died. More
  • no title provided in feed
    Americans' mental health issues are not identified and treated as readily as physical symptoms, especially among children - in part due to a shortage of clinicians. "We're looking for ways to integrate mental health into settings where children and families are every day," says Dr. More
  • no title provided in feed
    Mayor Donna Deegan speaks with CNN's Jake Tapper More
BING NEWS:
  • Zunveyl: An Improved Alzheimer's Drug With Fewer Side Effects Will Be Available Soon
    Zunveyl, an oral medication, is a better-tolerated version of galantamine for managing mild to moderate Alzheimer's symptoms.
    01/14/2025 - 7:30 am | View Link
  • Could New Leqembi Formulations Boost Lagging Sales in Alzheimer’s?
    The FDA accepted Biogen and Eisai’s BLA for a subcutaneous administration of the anti-amyloid antibody Monday as the partners await the regulator’s decision on a new intravenous regimen following an ...
    01/14/2025 - 2:40 am | View Link
  • FDA To Review Under the Skin Weekly Autoinjector For Biogen/Eisai's Alzheimer's Drug Leqembi
    Get Real-Time News and Alerts for Your Portfolio Leqembi is indicated for Alzheimer’s disease in patients with Mild Cognitive Impairment or mild dementia stage of the disease. A Prescription Drug User ...
    01/14/2025 - 12:04 am | View Link
  • Alzheimer’s Drugs Eyed as Next Big Obesity-Like Opportunity
    Firms developing Alzheimer’s drugs ... SA is expected to decide whether to continue developing bepranemab, though no timeline has been provided. A mid-stage study last year missed its primary endpoint ...
    01/9/2025 - 4:26 pm | View Link
  • IBX Excludes Coverage of Drugs with Accelerated Approvals for 18 Months
    Independence Blue Cross has begun excluding coverage for 18 months for therapies — but not cancer drugs — that have an accelerated approval based on a surrogate endpoint.
    01/7/2025 - 5:02 am | View Link
  • More

 

NEXT